MiNK Therapeutics (NASDAQ:INKT) Earns “Buy” Rating from HC Wainwright
MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 341.92% from the company’s previous close. MiNK Therapeutics Price […]
MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 341.92% from the company’s previous close. MiNK Therapeutics Price […]
